PATENT CLAIM ANALYSIS

Application Number: 15899707
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["514", "234200"]

Abstract:
The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R 1 , R 2  and R 3  which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.

Claim (Index 1):
A method of treating a cancer selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, breast cancer, triple negative breast cancer, melanoma, glioblastoma, prostate cancer, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancer, and a PTEN mutant cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof; wherein:\n the dotted lines [ . . . ] in the ring represent an optional bond which is be present in any stable combination; \n R 1  is selected from hydrogen and alkyl; \n R 2  is -A-R 4 ; \n A is arylene or tetrasubstituted arylene; wherein the substituent is halogen; \n R 3  is selected from hydroxy and amino; \n R 4  is selected from an aryl and a heteroaryl that is optionally substituted with one or more R 5 ; \n R 5  is selected from alkyl and \u2014(CH 2 ) n N(R a )R b ; \n R a  and R b  are independently selected from hydrogen, alkyl and \u2014C(O)alkyl; \n alternatively R a  and R b  can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and \n n is an integer selected from 0 and 1.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 88.0
- Lexical Diversity: 1.57143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13722807', '13227130', '11807354', '14979887', '13211026']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8041028833362666
- 35 USC 102 Novelty (BERT): 0.5243413898553757
- Combined Prediction Score: 0.7761267339881776
- Mean Citation Score: 327.236268
- Max Citation Score: 337.65573
- Similarity Product: 265.0045114475548

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test